DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lastacaft (Alcaftadine) - Summary

 
 



LASTACAFT SUMMARY

LASTACAFT™ is a sterile, topically administered H1 receptor antagonist containing alcaftadine for ophthalmic use.

LASTACAFT™ is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.


See all Lastacaft indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Lastacaft (Alcaftadine)

Pinkeye (Conjunctivitis)
Source: MedicineNet Ankylosing Spondylitis Specialty [2017.05.15]
Title: Pinkeye (Conjunctivitis)
Category: Symptoms and Signs
Created: 10/13/2003 12:00:00 AM
Last Editorial Review: 5/15/2017 12:00:00 AM

Make the Diagnosis: Red Eye, Green Discharge
Source: MedPage Today Surgery [2017.06.19]
(MedPage Today) -- Case Findings: A 17 year old male presents to your office with a red left eye. He says that last night he began having pain, redness, and irritation, and upon wakening today the symptoms were much more severe. At first the discharge was scant, but over the course of the day it worsened such that he has to continually wipe away "thick, green material. On exam, visual acuities are 6/6 in the right eye vs. 6/15 in the left eye. The right eye is not injected and normal on slit lamp examination. On examination of the left eye, there is severe injection and bogginess of the conjunctiva 360 degrees with abundant mucopurulent discharge. Peripheral corneal infiltrates and a 1+ cell reaction are also present. There is an enlarged preauricular lymph node on the left side. External appearance of the left eye is shown here. You suspect gonorrhea conjunctivitis and arrange for urgent antibiotic treatment. In addition to gonorrhea treatment, co-treatment of what infectious agent is recommended?

more news >>

Published Studies Related to Lastacaft (Alcaftadine)

Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. [2011.04]
PURPOSE: In this report, we characterize the in vitro pharmacokinetic properties of a new antihistamine, alcaftadine. In addition, we report results from phase 1 studies of several ophthalmic formulations of alcaftadine and examine the pharmacokinetic properties of one formulation in detail... CONCLUSIONS: Based upon pharmacokinetic and phase 1 studies, the novel antihistamine alcaftadine is an appropriate drug for use as an ophthalmic formulation for prevention and treatment of ocular allergic conditions such as allergic conjunctivitis (alcaftadine ophthalmic solution 0.25% was recently approved for use by the FDA). Topical administration of alcaftadine 0.25% ophthalmic solution was well tolerated and had an acceptable safety profile.

The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. [2011.03]
OBJECTIVE: The purpose of this study was to evaluate the safety and clinical efficacy of alcaftadine 0.25% ophthalmic solution, a new topical anti-allergic agent for the prevention of the signs and symptoms of allergic conjunctivitis induced by conjunctival allergen challenge (CAC)... CONCLUSIONS: With an onset of action within 3 minutes and a duration of action of at least 16 hours, the statistically and clinically significant effect of alcaftadine 0.25% on itching make it an important addition to therapy for ocular allergy. Additional studies are warranted to better understand the mechanisms affording a fast onset and prolonged duration of action.

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. [2011.02.08]
BACKGROUND: Antihistamines constitute the first line of therapy for allergic conjunctivitis, and are safe and effective in relieving the signs and symptoms of ocular allergy. Despite this, they are less effective than some other drugs in relieving delayed symptoms of allergic conjunctivitis. Recent evidence suggests that changes in the conjunctival epithelium may underlie aspects of delayed reactions. In this study we compared two antihistamines, olopatadine and alcaftadine, for their ability to modify epithelial cell changes associated with allergic conjunctivitis at time points selected to reflect late-phase reactions... CONCLUSION: Alcaftadine displays therapeutic properties beyond its antihistamine action. These include an ability to reduce conjunctival eosinophil recruitment, and a protective effect on epithelial tight junction protein expression.

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. [2011.01.13]
PURPOSE: To evaluate the effectiveness of alcaftadine 0.05%, 0.1%, and 0.25% ophthalmic solutions in treating the signs and symptoms of allergic conjunctivitis when compared with olopatadine hydrochloride 0.1% and placebo using the conjunctival allergen challenge (CAC) model... CONCLUSION: Treatment with alcaftadine 0.25% ophthalmic solution resulted in mean differences of >1 unit (ocular itching) and approximately >1 unit (conjunctival redness), which was significant (P < 0.001) compared with placebo treatment. All doses of alcaftadine were safe and well tolerated in the population studied.

Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. [2011]
Alcaftadine (Lastacaft®; Allergen, Inc.) is a broad-spectrum antihistamine displaying a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors...

more studies >>

Reports of Suspected Lastacaft (Alcaftadine) Side Effects

Ocular Hyperaemia (43)Eye Irritation (30)Eye Pruritus (23)Eye Pain (14)Eye Swelling (14)Scleral Hyperaemia (11)Somnolence (9)Erythema of Eyelid (8)Eyelid Oedema (7)Lacrimation Increased (7)more >>


Page last updated: 2017-06-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017